Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 10/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.39 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.34 |
| ▸ | MPO | P05164 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 3/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4531052 | 0.85 | MAPT (0.35) | TLR7TLR8MPOBACE1HRH4 | |
| SCHEMBL1232779 | 0.83 | TLR7 (0.38) | TLR7TLR8NLRP3MAP4K4BACE1 | |
| SCHEMBL205088 | 0.83 | BACE1 (0.34) | BACE1 | |
| SCHEMBL1233856 | 0.79 | MAP4K4 (0.40) | TLR7TLR8NLRP3MAP4K4BACE1 | |
| SCHEMBL203622 | 0.76 | BACE1 (0.33) | BACE1 | |
| SCHEMBL202425 | 0.73 | MAP4K4 (0.38) | MAP4K4HRH4 | |
| SCHEMBL30074855 | 0.71 | TLR7 (0.41) | TLR7TLR8 | |
| SCHEMBL29036543 | 0.71 | TLR7 (0.41) | TLR7TLR8 | |
| SCHEMBL29036535 | 0.71 | TRPV3 (0.40) | BACE1SSTR4 | |
| SCHEMBL30074849 | 0.71 | TRPV3 (0.40) | BACE1SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088788-B2 | Substituted fused[1,2] imidazo[4,5-c] ring compounds and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090221551-A1 | SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND METHODS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221551-A1 | SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND METHODS | IL2, IFNG, IL4 | TLR7 69/4885TLR8 217/4885NLRP3 1502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.